ANI Pharmaceuticals (ANIP) Expected to Post Quarterly Earnings on Thursday

ANI Pharmaceuticals (NASDAQ:ANIP) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect ANI Pharmaceuticals to post earnings of $2.18 per share and revenue of $280.26 million for the quarter. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. The business’s revenue was up 25.8% on a year-over-year basis. On average, analysts expect ANI Pharmaceuticals to post $7.76 EPS for the current fiscal year and $8.32 EPS for the next fiscal year.

ANI Pharmaceuticals Trading Up 1.1%

Shares of ANI Pharmaceuticals stock traded up $0.76 on Tuesday, hitting $71.42. The stock had a trading volume of 50,806 shares, compared to its average volume of 377,438. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a one year low of $69.58 and a one year high of $95.57. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of 15.40, a PEG ratio of 2.31 and a beta of 0.45. The stock’s 50-day simple moving average is $72.86 and its two-hundred day simple moving average is $77.62.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price objective on the stock. Finally, Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $99.60.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CEO Nikhil Lalwani sold 5,400 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $71.89, for a total value of $388,206.00. Following the sale, the chief executive officer directly owned 333,689 shares of the company’s stock, valued at $23,988,902.21. The trade was a 1.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Carey sold 2,850 shares of the business’s stock in a transaction that occurred on Thursday, October 29th. The stock was sold at an average price of $72.87, for a total value of $207,679.50. Following the completion of the sale, the chief financial officer directly owned 166,143 shares in the company, valued at approximately $12,106,840.41. This represents a 1.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 30,412 shares of company stock valued at $2,220,970. 8.10% of the stock is currently owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.